Biotech firm Aldagen and the University of California-Davis said this week that they plan to investigate if Aldagen’s adult stem-cell population can be used in a preclinical rat model of ischemic stroke, and if it can eventually play a role in creating drugs for other kinds of vascular or neurological disorders.
 
The collaboration will be the first to involve researchers at the UC-Davis Institute for Regenerative Cures, a new $62 million facility supported by the California Institute for Regenerative Medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.